Upgrade to SI Premium - Free Trial

Acadia Pharmaceuticals (ACAD) PT Lowered to $34 at BMO Capital Amid Heavy Selling

September 24, 2026 12:16 PM
BMO Capital analyst Evan David Seigerman lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $34.00 while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change Hot Comments

Next Articles